HUTCHMED (China) Limited (HCM)

16.36 -0.09 (-0.55%) At close: 04:00PM EDT

HUTCHMED (China) Limited

Cheung Kong Center
48th floor 2 Queen's Road Central
Hong Kong
Hong Kong
852 2121 8200
https://www.hutch-med.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 1,988

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Chi Keung To ACGI, B.Sc., M.B.A.	Executive Chairman	85k	N/A	1951
Mr. Chig Fung Cheng BEc, CA	CFO & Executive Director	962.15k	N/A	1967
Ms. Edith Shih BSE, C.S., CGP, EdM, FCIS, FCS, FCS(PE), M.A., P.E	Company Secretary & Non-Executive Director	N/A	N/A	1952
Dr. Karen Jane Atkin	Executive VP & COO	N/A	N/A	1966
David Ng	Head of Investor Relations & Capital Strategies	N/A	N/A	N/A
Mr. Charles George Rupert Nixon	Group General Counsel	N/A	N/A	1970
Mr. Kin Hung Lee M.B.A.	Senior Vice President of Corporate Management & Communications	N/A	N/A	1977
Ms. Selina Zhang	Senior Vice President of Global Human Resources	N/A	N/A	N/A
Dr. Qingmei Wang Ph.D.	Senior Vice President of Business Development & Strategic Alliances	N/A	N/A	1963
Mr. Hong Chen	Senior VP & Chief Commercial Officer- China	N/A	N/A	1970

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.

Corporate Governance

HUTCHMED (China) Limited’s ISS Governance QualityScore as of April 1, 2024 is 5. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 4; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.